The long-silent pharmaceutical segment industry has added another blockbuster product. On the evening of the 5th, the first batch of domestic vaccine ETFs and the first batch of Chinese medicine ETFs were approved.  

Specifically, the three vaccine ETFs approved this time came from three public offerings: Huatai Pineapple, Cathay Pacific, and Fuguo. These three products were declared on the same day, received the materials on the same day, and were approved on the same day. The approval document was obtained less than one month after the declaration; , ranging from reporting to approval.   

The indices tracked by these two batches of ETFs are the China Securities Traditional Chinese Medicine Index (930641.CSI) and the China Securities Vaccine Biotechnology Index ( 980015.CNI).   

Among them, the CSI Traditional Chinese Medicine Index was released on May 19, 2015, and 50 companies involved in the production and sales of traditional Chinese medicine were selected. The securities of listed companies are used as samples to reflect the overall performance of listed companies with the concept of traditional Chinese medicine. As of July 5, only 14 of the 50 samples in the index had a weight of more than 2%. Among them, the three samples of Pien Tze Huang (600436.SH), Yunnan Baiyao (000538.SZ), and Tongrentang (600085.SH) hadThe weights are 10.645%, 9.513%, and 7.95%, respectively.   

Currently, the only product tracking this index is China Universal CSI TCM LOF. As an over-the-counter index fund, the product was established on December 29, 2016, with a scale of 2.413 billion yuan in the first quarter of this year, and a return rate of 19.72% since its establishment.   

The National Certificate Vaccine Biotechnology Index includes biological products (vaccines, blood products, biological drugs, etc.), biological testing, biotechnology Select individual stocks in sub-sectors such as services. Sorted by the average daily total market value in the past half year, and selected from high to low until 50 sample stocks are selected. The index was released on February 16, 2015, and there are currently no products tracking the index.    The National Securities Index website shows that as of July 5, the samples with a weight of more than 5% are Hengrui Medicine (600276.SH), WuXi AppTec (603259.SH), Mindray Medical (300760.SZ) ), Changchun High-tech (000661.SZ), Zhifei Biological (300122.SZ).   

In addition to the 7 ETFs approved on the 5th, many other head fund companies are also intensively deploying vaccines and traditional Chinese medicines Thematic Fund.   

The fund administrative approval schedule announced by the China Securities Regulatory Commission shows that Harvest Fund submitted the A-share vaccine industry theme index on June 2. Application materials for sponsored funds. On June 10, Penghua Fund also submitted the application materials for its China Securities Vaccine and Biotechnology ETF to the China Securities Regulatory Commission, and China Asset Management reported a China Securities Vaccine and Biotechnology Index Sponsored Fund on the same day.   

Next, on June 17, Bosera, China Merchants and Harvest submitted the CSI Vaccine and Biotechnology ETF filing materials.   

At present, the above application materials have been received and are awaiting approval.   

Why do the vaccine and biotech industries gather together? Talking about the original intention of the layout, Cathay Pacific Fund stated that the "Vaccine Management Law" was officially promulgated in 2019 to promote the development of the vaccine industry. Under the influence of the new crown epidemic, my country's national emergency vaccine market for sudden infectious diseases has risen rapidly. The public's awareness of vaccination has been greatly improved. At the same time, investment activities in the vaccine field have risen rapidly, a large amount of capital has poured in, and local medium and large vaccine companies have been listed to achieve industrial upgrading. In general, the market demand for related industries is large, and the investment value of vaccines and biotechnology tracks is prominent.   

Penghua Quantitative and Derivatives Investment Department Fund Manager Zhang Yuxiang expressed his optimism about the prospects of traditional Chinese medicine. At the bottom of the period of confusion and predicament, it is expected to usher in a reversal of difficulties in 2022; in recent years, the state has vigorously supported the development of traditional Chinese medicine, and has continuously introduced relevant policies. Logic; in the context of the correction in the valuation of the overall pharmaceutical sector, the traditional Chinese medicine sector is expected to usher in valuation remodeling as a low valuation and policy haven.